Tibet Rhodiola Pharmaceutical Holding

Tibet Rhodiola Pharmaceutical Holding ROCE

The Return on Capital Employed (ROCE) of Tibet Rhodiola Pharmaceutical Holding (600211.SS) as of Nov 2, 2026 is 22.20 %. In the previous year, Return on Capital Employed (ROCE) was 29.36 % — a change of -24.40% (lower).

ROCE

22.20 %

YoY

-24.40%

Last updated:

In 2025, Tibet Rhodiola Pharmaceutical Holding's return on capital employed (ROCE) was 22.20 %, a -24.40% increase from the 29.36 % ROCE in the previous year.

The Tibet Rhodiola Pharmaceutical Holding ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
10.81 CNY
Jan 1, 2019
14.35 CNY
Jan 1, 2020
18.24 CNY
Jan 1, 2021
9.71 CNY
Jan 1, 2022
15.33 CNY
Jan 1, 2023
26.65 CNY
Jan 1, 2024
29.36 CNY
Jan 1, 2025
22.20 CNY
The Tibet Rhodiola Pharmaceutical Holding ROCE history
YEARROCEYoY
22.20 %-24.40%
29.36 %+10.18%
26.65 %+73.83%
15.33 %+57.91%
9.71 %-46.77%
18.24 %+27.07%
14.35 %+32.76%
10.81 %+3.60%
10.44 %-65.27%
30.05 %+36.91%
21.95 %+254.53%
6.19 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Tibet Rhodiola Pharmaceutical Holding Stock analysis

What does Tibet Rhodiola Pharmaceutical Holding do? Tibet Rhodiola Pharmaceutical Holding Co. generates revenue through the manufacture and wholesale of pharmaceutical products. The company distributes proprietary drug products and processes pharmaceuticals, serving markets across South China, North China, East China, Central China, and overseas regions. Its primary customers are pharmaceutical distributors and healthcare providers within these regions, focusing on the distribution of its proprietary drug portfolio. The firm's revenue streams are derived from the wholesale of manufactured pharmaceuticals and the processing of pharmaceutical products. It operates through a network of distributors in key Chinese regions and overseas markets, targeting healthcare institutions and pharmacies that require its proprietary drug solutions. The company's business model emphasizes regional distribution networks to reach its target segments efficiently. Tibet Rhodiola Pharmaceutical Holding Co. relies on its proprietary drug products for sales, with a strong presence in multiple Chinese regions and overseas markets. The company's revenue is driven by the distribution of these products through its established wholesale channels, catering to the healthcare sector's demand for pharmaceutical solutions in its operational areas. Tibet Rhodiola Pharmaceutical Holding is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Tibet Rhodiola Pharmaceutical Holding's Return on Capital Employed (ROCE)

Tibet Rhodiola Pharmaceutical Holding's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Tibet Rhodiola Pharmaceutical Holding's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Tibet Rhodiola Pharmaceutical Holding's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Tibet Rhodiola Pharmaceutical Holding’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Tibet Rhodiola Pharmaceutical Holding stock

Return on Capital Employed (ROCE) of Tibet Rhodiola Pharmaceutical Holding is 22.20 % in 2025.

Return on Capital Employed (ROCE) of Tibet Rhodiola Pharmaceutical Holding changed from 29.36 % to 22.20 %, representing a -24.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Tibet Rhodiola Pharmaceutical Holding since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Tibet Rhodiola Pharmaceutical Holding with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Tibet Rhodiola Pharmaceutical Holding

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Tibet Rhodiola Pharmaceutical Holding